Anthera Pharmaceuticals, Inc.
|
Seite 1 von 5
neuester Beitrag: 24.04.21 23:43
|
||||
| eröffnet am: | 11.01.13 17:18 von: | Bäcker33 | Anzahl Beiträge: | 101 |
| neuester Beitrag: | 24.04.21 23:43 von: | Doreenwwlia | Leser gesamt: | 22280 |
| davon Heute: | 4 | |||
| bewertet mit 2 Sternen |
||||
|
2 |
3 |
4 |
5
| 5
|
||||
Thread abonnieren
|
--button_text--
interessant
|
|
witzig
|
|
gut analysiert
|
|
informativ
|
1
Jefferies & Company, Inc. agiert als alleiniger Book-Running-Manager handeln im Angebot und Leerink Swann LLC als Co-Manager tätig. Trout Capital LLC als Berater für das Unternehmen tätig.
Die Wertpapiere oben beschrieben wurden von der Gesellschaft im Rahmen eines Shelf Registration Statement zuvor mit eingereicht, angeboten und für gültig erklärt durch, der Securities and Exchange Commission ("SEC"). Eine endgültige Nachtrag zum Prospekt und begleitende Prospekt für das Angebot wurde bei der SEC eingereicht und ist auf der Website der SEC unter http://www.sec.gov . Eigenkapital Syndicate Prospectus Department, 520 Madison Avenue, 12th Floor, New York, NY 10022, oder telefonisch unter: Kopien des endgültigen Prospekts Ergänzung und der damit einhergehenden Prospektes im Zusammenhang mit diesem Angebot kann von Jefferies & Company, Inc., Attention erhalten werden, 877 -547-6340 oder per E-Mail Prospectus_Department@Jefferies.com . 877-547-6340
Diese Pressemitteilung stellt weder ein Angebot zum Verkauf oder eine Aufforderung zur Abgabe eines Angebots zum Kauf, noch wird es keinen Verkauf der sein, diese Wertpapiere in einem Staat oder anderen Jurisdiktionen, in denen ein solches Angebot, eine solche Aufforderung oder Verkauf ungesetzlich wäre vor der Registrierung oder Qualifikation unter den Wertpapiergesetzen eines solchen Staates oder der Gerichtsbarkeit.
Über Anthera Pharmaceuticals
Anthera Pharmaceuticals ist ein biopharmazeutisches Unternehmen auf die Entwicklung und Vermarktung von Produkten zu schweren Erkrankungen, die mit Entzündungen und Autoimmunerkrankungen zu behandeln konzentriert.
Safe Harbor Statement
Alle Aussagen in dieser Pressemitteilung, die sich auf zukünftige Ereignisse oder andere nicht-historische Fragen, einschließlich Aussagen, die vorausgegangen sind, gefolgt von, oder die solche Worte sind als Bezug enthalten "schätzen", "beabsichtigen", "erwarten", "glauben", "planen", "Ziel", "erwarten", "projizieren", oder ähnliche Aussagen sind zukunftsgerichtete Aussagen im Sinne der Safe-Harbor-Bestimmungen des Private Securities Litigation Reform Act von 1995. Diese zukunftsbezogenen Aussagen beinhalten Aussagen über die Erwartungen des Unternehmens in Bezug auf seine öffentlichen Angebots, einschließlich Aussagen über die beabsichtigte Verwendung der Erlöse aus dem Börsengang. Solche Aussagen basieren auf den Erwartungen des Unternehmens zum Zeitpunkt dieser Pressemitteilung und unterliegen bestimmten Risiken und Unsicherheiten, welche die tatsächlichen Ergebnisse wesentlich abweichen, einschließlich, aber nicht diejenigen, die in der Gesellschaft öffentlichen Einreichungen bei der SEC beschränkt könnte, einschließlich der Jahresbericht des Unternehmens auf Formblatt 10-K für das Geschäftsjahr zum 31. Dezember 2011 und im Quartalsbericht auf Formblatt 10-Q für das Quartal zum 30. September 2012. Das Unternehmen lehnt jegliche Absicht oder Verpflichtung zur Aktualisierung jeglicher zukunftsgerichteter Aussagen zu aktualisieren, sei es aufgrund neuer Informationen, zukünftiger Ereignisse oder anderweitig, sofern dies nicht gesetzlich vorgeschrieben ist.
KONTAKT: Bianca Nery der Anthera Pharmaceuticals, Inc., bnery@anthera.com oder 510.856.5586 . 510.856.5586
@ Yahoofinance auf Twitter, ein Fan auf sich Facebook
Optionen
2
1
Another name in the biotechnology and drugs complex that insiders are active in here is Anthera Pharmaceuticals (ANTH), which is focused on developing and commercializing products to treat serious diseases associated with inflammation, including cardiovascular and autoimmune diseases. Insiders are buying this stock into a steep decline, since shares are off by 39% during the last six months.
Anthera Pharmaceuticals has a market cap of $52 million and an enterprise value of $33 million. This stock trades at a premium valuation, with a price-to-book of 9.84. Its estimated growth rate for this year is 54.9%, and for next year it’s pegged at 68.7%. This is a cash-rich company, since the total cash position on its balance sheet is $42.46 million and its total debt is $22.62 million. After you back out the debt, this company has $19.84 million in cash on its books.
A director just bought 1.8 million shares, or about $1.14 million worth of stock, at 65 cents per share.
From a technical perspective, ANTH is currently trending below both its 50-day and 200-day moving averages, which is bearish. This stock has been downtrending over the last month, with shares dropping from its high of 84 cents to its recent low of 64 cents per share. During that downtrend, shares of ANTH have been mostly making lower highs and lower lows, which is bearish technical price action. That said, shares of ANTH have started to bounce off that 64 cents per share low and quickly moving within range of triggering a near-term breakout trade.
If you’re in the bull camp on ANTH, then I would look for long-biased if this stock manages to break out above its 50-day at 68 cents per share and then once it clears more overhead resistance at 70 to 72 cents per share with high volume. Look for a sustained move or close above those levels with volume that registers near or above its three-month average volume of 1.6 million shares. If that breakout triggers soon, then ANTH will set up to re-test or possibly take out its next major overhead resistance levels at 80 to 84 cents per share. Any high-volume move above 84 cents per share will then put $1 to $1.17 into focus for shares of ANTH.
Optionen
1
Optionen
0
23:30 07.02.13
PR Newswire
HAYWARD, Calif., Feb. 7, 2013
HAYWARD, Calif., Feb. 7, 2013 /PRNewswire/ -- Anthera Pharmaceuticals, Inc. (Nasdaq: ANTH) a biopharmaceutical company developing drugs to treat serious diseases associated with inflammation and autoimmune disorders, today announced Paul F. Truex, Anthera's President and Chief Executive Officer, will present at the 2013 Leerink Global Healthcare Conference in New York, NY on Thursday, February 14, 2013 at approximately 8:00 am Eastern Time.
2013 Leerink Global Healthcare Conference Presentation
Date/Time: Thursday, February 14, at 8:00 am Eastern Time
Location: The Waldorf Astoria New York
About Anthera Pharmaceuticals
Anthera Pharmaceuticals is a biopharmaceutical company focused on developing and commercializing products to treat serious diseases associated with inflammation and autoimmune diseases.
CONTACT: Bianca Nery of Anthera Pharmaceuticals, Inc., bnery@anthera.com or 510.856.5586.
SOURCE Anthera Pharmaceuticals, Inc. at the 2013 Leerink Global Healthcare Conference
23:30 07.02.13
PR Newswire
HAYWARD, Calif., Feb. 7, 2013
HAYWARD, Calif., Feb. 7, 2013 /PRNewswire/ -- Anthera Pharmaceuticals, Inc. (Nasdaq: ANTH) a biopharmaceutical company developing drugs to treat serious diseases associated with inflammation and autoimmune disorders, today announced Paul F. Truex, Anthera's President and Chief Executive Officer, will present at the 2013 Leerink Global Healthcare Conference in New York, NY on Thursday, February 14, 2013 at approximately 8:00 am Eastern Time.
2013 Leerink Global Healthcare Conference Presentation
Date/Time: Thursday, February 14, at 8:00 am Eastern Time
Location: The Waldorf Astoria New York
About Anthera Pharmaceuticals
Anthera Pharmaceuticals is a biopharmaceutical company focused on developing and commercializing products to treat serious diseases associated with inflammation and autoimmune diseases.
CONTACT: Bianca Nery of Anthera Pharmaceuticals, Inc., bnery@anthera.com or 510.856.5586.
SOURCE Anthera Pharmaceuticals, Inc.
Optionen
0
Posted by Bonnie Powley on Mar 5th, 2013 // No Comments
Jefferies Group started coverage on shares of Anthera Pharmaceuticals (NASDAQ: ANTH) in a research note issued on Tuesday. The firm set a ?buy? rating and a $2.00 price target on the stock.
Shares of Anthera Pharmaceuticals opened at 0.571 on Tuesday. Anthera Pharmaceuticals has a 52 week low of $0.49 and a 52 week high of $6.54. The stock?s 50-day moving average is currently $0.6. The company?s market cap is $45.2 million.
Anthera Pharmaceuticals, Inc. (Anthera) is a biopharmaceutical company focused on developing and commercializing products to treat serious diseases associated with inflammation, including cardiovascular and autoimmune diseases.
Optionen
0
http://www.shortsqueeze.com/?symbol=anth
Anthera Pharmaceuticals Incorporated $ 0.57
ANTH -0.03
Daily Short Sale Volume view
Short Interest (Shares Short) 9,287,100
Days To Cover (Short Interest Ratio) 5.9
Short Percent of Float 17.55 %
Short Interest - Prior 8,676,900
Short % Increase / Decrease 7.03
Daily Naked Short Selling List view
Short Squeeze Ranking? view
% From 52-Wk High ($ 0.00 ) %
% From 52-Wk Low ($ 0.00 ) %
% From 200-Day MA ($ ) %
% From 50-Day MA ($ ) %
Price % Change (52-Week) %
Shares Float 52,910,000
% Owned by Insiders 45.59%
% Owned by Institutions 17.00%
Market Cap. $
Trading Volume - Today 1,137,386
Trading Volume - Average 1,583,700
Trading Volume - Today vs. Average 71.82%
Earnings Per Share
PE Ratio
Record Date 2013-FebB
Sector
Industry
Exchange NAS
Optionen
1
Press Release: Anthera Pharmaceuticals, Inc. ? 50 minutes ago
RecommendTweet1
RELATED QUOTES
Symbol Price Change §
ANTH 0.63
§
HAYWARD, Calif., March 22, 2013 /PRNewswire/ -- Anthera Pharmaceuticals, Inc. (ANTH), a biopharmaceutical company developing drugs to treat serious diseases associated with inflammation and autoimmune disorders, today announced its abstract entitled "Blisibimod, an Emerging Subcutaneous Biologic Therapy for Patients with Active, Moderate-to-Severe Systemic Lupus Erythematosus," has been selected as an oral presentation and will be presented at the 10th International Congress on Systemic Lupus Erythematosus by Dr. Morton Scheinberg, a rheumatologist at the Hospital Abreu Sodre Pesquisa Clinica in Sao Paulo, Brazil, on April 20, 2013.
Additionally, a poster entitled "Clinical Experience in Latin America With Blisibimod Amongst Subjects with Active, Moderate-to-Severe Systemic Lupus Erythematosus: Data From The Phase 2b PEARL-SC Study," will be presented by Dr. Scheinberg as part of the conferences Guided Poster Tours on April 19, 2013.
The poster will be available on www.anthera.com.
About Blisibimod and PEARL-SC
BAFF has been associated with a wide range of B-cell-mediated autoimmune diseases, including systemic lupus erythematosus, vasculitis, IgA nephropathy, immune thrombocytopenic purpura and others. Multiple clinical studies with other BAFF antagonists recently have reported on BAFF inhibitors potential positive role in treating lupus and rheumatoid arthritis. Anthera is advancing its development of blisibimod, a selective inhibitor of BAFF, to expand its potential clinical utility in autoimmune diseases. Blisibimod is a novel fusion protein called a peptibody and is distinct from an antibody. Anthera owns worldwide rights to blisibimod in all potential indications. The PEARL-SC Phase 2 study was designed as a randomized, double-blind, placebo-controlled, dose-ranging trial to evaluate the safety, tolerability and efficacy of blisibimod plus standard of care, versus placebo plus standard of care. A total of 547 patients with active SLE were randomized to receive one of three different doses of blisibimod or placebo (100 mg weekly, 200 mg weekly or 200 mg monthly) administered subcutaneously over a minimum 24-week treatment period, in addition to standard-of-care therapy. The study was conducted at multiple centers worldwide.
About Anthera Pharmaceuticals
Anthera Pharmaceuticals is a biopharmaceutical company focused on developing and commercializing products to treat serious diseases associated with inflammation and autoimmune diseases.
Safe Harbor Statement
Any statements contained in this press release that refer to future events or other non-historical matters, including statements that are preceded by, followed by, or that include such words as "estimate," "intend," "anticipate," "believe," "plan," "goal," "expect," "project," or similar statements, are forward-looking statements made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. These forward-looking statements are based on Anthera's expectations as of the date of this press release and are subject to certain risks and uncertainties that could cause actual results to differ materially as set forth in Anthera's public filings with the SEC, including Anthera's Annual Report on Form 10-K for the year ended December 31, 2011 and Quarterly Report on Form 10-Q for the quarter ended September 30, 2012. Anthera disclaims any intent or obligation to update any forward-looking statements, whether because of new information, future events or otherwise, except as required by applicable law.
CONTACT: Bianca Nery of Anthera Pharmaceuticals, Inc., bnery@anthera.com or 510.856.5586.
Optionen
0
Press Release : Anthera Pharmaceuticals, Inc. - vor 10 Stunden
ÄHNLICHE KURSE
Symbol Preis Ändern §
ANTH 0,64 -0,01
§
HAYWARD, Kalifornien, March 27, 2013 / PRNewswire / - Anthera Pharmaceuticals, Inc. ( ANTH ), ein biopharmazeutisches Unternehmen, das Medikamente zu schweren Erkrankungen mit Entzündungen und Autoimmunerkrankungen zu behandeln, gab heute bekannt, dass es die CHABLIS-SC1 Phase 3 eingeleitet Studie blisibimod, a novel Inhibitor der B-Zell-Aktivierungsfaktor (BAFF) für die Behandlung von systemischem Lupus erythematodes (Lupus). Lupus ist eine chronische Autoimmunerkrankung, die häufig zu schweren Hautausschlag, Müdigkeit, Gelenkschmerzen und Hauptorgan Komplikationen.
Die Phase 3 CHABLIS-SC1 Studie ist eine multizentrische, placebo-kontrollierte, randomisierte, doppel-blinde Studie zur Beurteilung der Wirksamkeit, Sicherheit, Verträglichkeit und Immunogenität des blisibimod bei Patienten mit klinisch aktiven SLE (SELENA-SLEDAI bewerten > 10), die nicht über erreicht eine optimale Lösung ihrer Erkrankung mit Kortikosteroiden. Die Studie wird Patienten aus Lateinamerika, Asien-Pazifik und der Gemeinschaft Unabhängiger Staaten, die randomisiert blisibimod oder Placebo für 52 Wochen nach dem sie die Möglichkeit, blisibimod Therapie in einer open-label, langfristige erhalten haben, folgen Sie erhalten werden -up Studie zur Sicherheit. Die Studie wird etwa 400 Patienten und der primäre Endpunkt wird ein systemischer Lupus erythematodes Response Index-8 (SRI-8) sein. Ein SRI-8 Responder als einem Patienten, der eine Verringerung der SELENA-SLEDAI gleich oder größer als 8 Punkte erreicht hat definiert ist und keine neuen BILAG A oder zwei B Organ Domäne Scores und keine Erhöhung des Arztes Global Assessment (PGA) von größer als 0,3 auf einem Drei-Punkt-Skala. Als Teil der CHABLIS-SC1 klinischen Studie eine unabhängige Statistiker befragen Zwischenbericht Analysen zu wichtigen Studie Annahmen zu validieren. Eine Zusammenfassung dieser Untersuchungen werden später im Jahr 2013 veröffentlicht werden.
Das Design des CHABLIS-SC1 Studie basiert auf einer prospektiven Subgruppenanalyse in der Phase-2b-PEARL-SC-Studie, die im Juli 2012 berichtet wurde durchgeführt ausgesagt. In dieser Analyse wurde eine signifikante Verbesserung der SRI-8 in Patienten, die subkutane blisibimod (200mg QW) im Vergleich zu den behandelten Standard-Therapie mit Steroiden (N = 95, 41,7% versus 10,4%, p erhielten, beobachtet
"Der Beginn der CHABLIS-SC1 Studie markiert einen wichtigen Meilenstein für Anthera. Die Erkenntnisse aus unseren klinische Phase-2b-Studie stützt unsere Überzeugung, dass blisibimod kann eine sehr wirksame Behandlungsoption für die mehr schwerkranken Lupus-Patienten im Vergleich zu derzeit verfügbaren Therapeutika, sein" sagte Colin Hislop, MD, Anthera Chief Medical Officer. "Wir freuen uns, blisibimod die Entwicklung voranzutreiben. Heute haben wir einen weiteren Schritt, um eine dringend benötigte Behandlung für diese unvorhersehbar und verheerende Krankheit genommen."
Über B-Zell-aktivierende Faktor (BAFF) und blisibimod
BAFF hat mit einer Vielzahl von B-Zell-vermittelten Autoimmunerkrankungen, einschließlich systemischer Lupus erythematodes, IgA-Nephropathie, Lupus Nephritis, rheumatoide Arthritis, multiple Sklerose, Sjögren-Syndrom, Basedow-Krankheit und andere in Verbindung gebracht. Mehrere klinische Studien mit anderen BAFF Antagonisten kürzlich auf dem Potential am positiven Rolle BAFF-Inhibitoren bei der Behandlung von rheumatoider Arthritis und Lupus bei gleichzeitiger Abnahme der B-Zellen, Plasmazellen und Autoantikörpern gemeldet. Anthera treibt seine Entwicklung blisibimod ein breites Inhibitor der BAFF, sein Potenzial klinischen Nutzen bei Autoimmunerkrankungen zu erweitern. Blisibimod ist ein neues Protein von hochaffinen BAFF Bindungsdomänen fusioniert an eine humane Fc-Domäne kompromittiert, genannt Peptibody und unterscheidet sich von einem Antikörper. Anthera besitzt die weltweiten Rechte an allen möglichen Indikationen blisibimod.
Über Anthera Pharmaceuticals
Anthera Pharmaceuticals ist ein biopharmazeutisches Unternehmen auf die Entwicklung und Vermarktung von Produkten zu schweren Erkrankungen mit Entzündungen und Autoimmunerkrankungen zu behandeln konzentriert.
Safe Harbor Statement
Alle Aussagen in dieser Pressemitteilung, die sich auf zukünftige Ereignisse oder andere nicht-historische Fragen, einschließlich Aussagen, die vorausgegangen sind, gefolgt von, oder die solche Worte sind wie unter "schätzen", "beabsichtigen", "erwarten", "glauben, "," planen "," Ziel "," erwarten "," projizieren ", oder ähnliche Aussagen sind zukunftsgerichtete Aussagen im Sinne der Safe-Harbor-Bestimmungen des Private Securities Litigation Reform Act von 1995. Diese zukunftsgerichteten Aussagen beruhen auf Anthera Erwartungen zum Zeitpunkt der Veröffentlichung dieser Pressemitteilung und unterliegen bestimmten Risiken und Unsicherheiten, welche die tatsächlichen Ergebnisse erheblich abweichen, wie in öffentlichen Einreichungen Anthera bei der SEC, einschließlich Geschäftsbericht Anthera die am Set könnte Form 10-K für das Geschäftsjahr zum 31. Dezember 2012. Anthera lehnt jegliche Absicht oder Verpflichtung zur Aktualisierung jeglicher zukunftsgerichteter Aussagen zu aktualisieren, sei es aufgrund neuer Informationen, zukünftiger Ereignisse oder anderweitig, sofern dies nicht gesetzlich vorgeschrieben ist.
KONTAKT: Bianca Nery der Anthera Pharmaceuticals, Inc., bnery@anthera.com oder 510.856.5586.
@ Yahoofinance auf Twitter, ein Fan auf sich Facebook
Optionen
1
1
Anthera Refinances Existing Debt with New $20 Million Credit Facility and Secures $18.5 Million Committed Equity Financing Facility
Debt Related Expense to Decrease by Over $600K per Month through 2014
Press Release: Anthera Pharmaceuticals, Inc. ? 11 hours ago
RELATED QUOTES
Symbol Price Change §
ANTH 0.64 -0.01
§
HAYWARD, Calif., April 5, 2013 /PRNewswire/ -- Anthera Pharmaceuticals, Inc. (ANTH), a biopharmaceutical company developing drugs to treat serious diseases associated with inflammation, today announced that it has secured a new $20.0 million debt financing facility through a syndicate led by MidCap Financial SBIC, LP ("MidCap Financial"). Anthera will use the loan proceeds to refinance the remaining principal of the loan agreement entered into with Hercules Technology Growth Capital, Inc. in 2011 and for general corporate purposes. MidCap Financial will receive warrants to purchase an aggregate of 588,235 shares of Anthera's common stock at an exercise price of $0.68.
"The favorable terms of the new debt financing facility, coupled with our January 2013 equity financing of approximately $43.0 million of net proceeds, provides the liquidity we need to deliver key milestones for 2013 and 2014," said Chris Lowe, Anthera's Chief Business Officer and Chief Financial Officer.
Additionally, Anthera has entered into an $18.5 million common stock purchase agreement with Lincoln Park Capital Fund, LLC ("LPC") a Chicago-based institutional investor. Upon executing the agreement, LPC made an initial purchase of $2,000,000 in common stock from Anthera at a purchase price of $0.648 per share. Furthermore, for a period of two years, Anthera has the right to sell up to an additional $16.5 million of its common stock to LPC at prices that are generally determined by the Company. Anthera expects to use the proceeds from this transaction for servicing long-term debt and working capital.
Under the terms of the agreement, there are no upper limits to the price that LPC may pay to purchase Anthera's common stock. Anthera will control the timing of any future sales and the amount of shares to be sold. LPC has no right to require any sales and is obligated to purchase the common stock as directed by Anthera. Under the terms of the agreement, LPC has covenanted not to cause or engage in any manner whatsoever, any direct or indirect short selling or hedging of Anthera's shares of common stock. In consideration for entering into the agreement, Anthera may issue up to 898,059 of additional shares to LPC as a commitment fee, depending upon the actual amount drawn from the equity line. The shares covered under the agreement are the subject of a prospectus supplement pursuant to Anthera's effective shelf registration statement and base prospectus contained therein.
The descriptions of the financings in this press release do not purport to be a complete description. Additional details regarding these financings are included in a Current Report on Form 8-K filed on April 5, 2013 by the Company with the Securities and Exchange Commission.
About Anthera Pharmaceuticals
Anthera Pharmaceuticals is a biopharmaceutical company focused on developing and commercializing products to treat serious diseases associated with inflammation and autoimmune disorders.
About MidCap Financial
MidCap Financial is a commercial finance company focused on middle market lending across the healthcare sector. MidCap specializes in $5 million to $200 million loans and since launching in 2008 has deployed over $1 billion in capital. The company is headquartered in Bethesda, MD, with offices in Chicago and Los Angeles. For more information, please visit www.midcapfinancial.com
About Lincoln Park Capital Fund, LLC ("LPC")
LPC is an institutional investor headquartered in Chicago, Illinois. LPC's experienced professionals manage a portfolio of investments in public and private entities. These investments are in a wide range of companies and industries emphasizing life sciences, specialty financing, energy and technology. LPC's investments range from multiyear financial commitments to fund growth to special situation financings to long-term strategic capital offering companies certainty, flexibility and consistency. For more information, visit www.lpcfunds.com.
Safe Harbor Statement
Any statements contained in this press release that refer to future events or other non-historical matters, including statements that are preceded by, followed by, or that include such words as "estimate," "intend," "anticipate," "believe," "plan," "goal," "expect," "project," or similar statements, are forward-looking statements made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. These forward-looking statements are based on Anthera's expectations as of the date of this press release and are subject to certain risks and uncertainties that could cause actual results to differ materially as set forth in Anthera's public filings with the SEC, including Anthera's Annual Report on Form 10-K for the year ended December 31, 2012. Anthera disclaims any intent or obligation to update any forward-looking statements, whether because of new information, future events or otherwise, except as required by applicable law.
CONTACT: Chris Lowe of Anthera Pharmaceuticals, Inc., pr@anthera.com or 510.856.5600.
@yahoofinance on Twitter, become a fan on Facebook
Optionen
1
By PR Newswire, June 24, 2013, 08:30:00 AM EDT
Vote up
HAYWARD, Calif., June 24, 2013 /PRNewswire/ -- Anthera Pharmaceuticals, Inc. (Nasdaq:ANTH), a biopharmaceutical company developing drugs to treat serious diseases associated with autoimmune disorders, today announced it has initiated the BRIGHT-SC Phase 2 study of blisibimod, a novel inhibitor of B-Cell Activating Factor (BAFF) for the treatment of IgA nephropathy. IgA nephropathy is a chronic autoimmune renal disease characterized by proteinuria and progression to end stage renal disease.
BRIGHT-SC is a multicenter, placebo-controlled, double-blind, Phase 2 clinical study that is expected to enroll at least 48 patients from Asia Pacific geographies. Patients will be randomized into one active treatment arm or one placebo arm. The primary endpoint of the study will be a reduction in proteinuria at 32 weeks. The Company plans to conduct an interim analysis of proteinuria after patients have completed 8 weeks of therapy. Secondary endpoints will include the effects of blisibimod on estimated Glomerular Filtration Rate (eGFR), plasma B cells, and other biomarkers of kidney disease.
In May, the company met with the US FDA to discuss the future of the IgA nephropathy development plan. "We are encouraged by the outcome of our pre-Investigational New Drug meeting with the FDA. The use of proteinuria as a primary endpoint in studies of IgA nephropathy was well received by the agency," said Paula Adams, PhD, Anthera's Vice President of Regulatory Affairs and Compliance. "Data from the BRIGHT-SC study design will be helpful in our efforts to obtain an accelerated approval for blisibimod in this potential orphan indication." In the coming weeks the Company will be meeting with the Japanese Pharmaceutical Medical Devices Agency to explore development strategies in Japan.
About B-Cell Activating Factor (BAFF) and Blisibimod
BAFF has been associated with a wide range of B-cell-mediated autoimmune diseases, including systemic lupus erythematosus, IgA nephropathy, lupus nephritis, rheumatoid arthritis, multiple sclerosis, Sjogren's Syndrome, Graves' Disease and others. Multiple clinical studies with other BAFF antagonists recently have reported on the potential positive role on BAFF inhibitors in treating lupus and rheumatoid arthritis with concomitant decreases in B-cells, plasma cells and autoantibodies. Anthera is advancing its development of blisibimod, a broad inhibitor of BAFF, to expand its potential clinical utility in autoimmune diseases. Blisibimod is a novel protein compromised of high-affinity BAFF binding domains fused to a human Fc domain, called a peptibody and is distinct from an antibody. Anthera owns worldwide rights to blisibimod in all potential indications.
About Anthera Pharmaceuticals
Anthera Pharmaceuticals is a biopharmaceutical company focused on developing and commercializing products to treat serious diseases associated with inflammation and autoimmune disorders.
Safe Harbor Statement
Any statements contained in this press release that refer to future events or other non-historical matters, including statements that are preceded by, followed by, or that include such words as "estimate," "intend," "anticipate," "believe," "plan," "goal," "expect," "project," or similar statements, are forward-looking statements made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. These forward-looking statements include statements about the Company's expectations with respect to its proposed offering, including its intention to offer and sell shares, its intention to grant the underwriters an option to purchase additional shares and its intended use of proceeds from the offering. Such statements are based on the Company's expectations as of the date of this press release and are subject to certain risks and uncertainties that could cause actual results to differ materially, including but not limited to the risks and uncertainties associated with market conditions and the satisfaction of customary closing conditions related to the proposed offering, as well as those set forth in the Company's public filings with the SEC, including the Company's Annual Report on Form 10-K for the year ended December 31, 2012 and Quarterly Report on Form 10-Q for the quarter ended March 31, 2013. The Company disclaims any intent or obligation to update any forward-looking statements, whether because of new information, future events or otherwise, except as required by applicable law.
CONTACT: Dennis Lutz of Anthera Pharmaceuticals, Inc., dlutz@anthera.com or (510)856-5598.
SOURCE Anthera Pharmaceuticals, Inc.
This article appears in: News Headlines
Referenced Stocks: ANTH
Read more: http://www.nasdaq.com/press-release/...d-20130624-00355#ixzz2X8Z8YtEu
